Corcept Therapeutics (CORT) director exercises 30K options and gifts shares
Rhea-AI Filing Summary
Corcept Therapeutics director David L. Mahoney reported a series of routine equity transactions. He exercised stock options covering 30,000 shares of Common Stock at $5.86 per share, converting a derivative position into directly held shares.
To cover the exercise price through a net, cashless exercise, 5,469 shares were withheld at a value of $32.15 per share, which is a tax/payment mechanism rather than an open-market sale. The remaining 24,531 shares were transferred as a bona fide gift to the David L. Mahoney and Winnifred C. Ellis 1998 Family Trust and are now reported as indirectly owned.
After these transactions, Mahoney reports 1,237,145 shares of Common Stock held indirectly through the family trust and an additional 46,147 shares held indirectly through The Black Dog Private Foundation. The filing shows no open-market purchases or sales of Corcept Therapeutics stock.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) | 30,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 30,000 | $5.86 | $176K |
| Exercise Price or Tax Liability | Common Stock | 5,469 | $32.15 | $176K |
| Gift | Common Stock | 24,531 | $0.00 | $0.00 |
| Other | Common Stock | 24,531 | $0.00 | $0.00 |
| holding | Common Stock | -- | -- | -- |
Footnotes (3)
- F1. These shares were withheld so the Reporting Person could satisfy the exercise price arising from a net (cashless) exercise of stock options.
- F2. Transfer of shares without consideration to the David L. Mahoney and Winnifred C. Ellis 1998 Family Trust.
- F3. Fully exercisable.
FAQ
What did Corcept Therapeutics (CORT) director David L. Mahoney do in this Form 4?
What is the role of tax withholding in Mahoney’s Corcept Therapeutics Form 4?
What other indirect Corcept Therapeutics holdings does Mahoney report?
AI-generated analysis. How Rhea-AI works. Not financial advice.